Research Topics
| Rokea A el-AzharySummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
A new patient education approach in contact allergic dermatitis: the Contact Allergen Replacement Database (CARD)Rokea A el-Azhary
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Dermatol 43:278-80. 2004..At the same time, dermatologists may spend a considerable amount of time trying to educate their patients about the avoidance of these allergens and explaining which products may contain them...- Antihistone antibodies in linear scleroderma variantsRokea A el-Azhary
Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA
Int J Dermatol 45:1296-9. 2006..Antihistone antibodies (AHAs), which traditionally are markers for drug-induced lupus, may also be linked to linear scleroderma... - Azathioprine: current status and future considerationsRokea A el-Azhary
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Dermatol 42:335-41. 2003 - Sclerotherapy of spider veins using the accurate depth-gauge collagen needleRokea A el-Azhary
Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA
Int J Dermatol 47:205-6. 2008 - Sweet syndrome as a manifestation of azathioprine hypersensitivityRokea A el-Azhary
Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 83:1026-30. 2008..Antibiotic therapy failed in all patients, but Sweet syndrome resolved with drug withdrawal and prednisone therapy. Because azathioprine is widely used, clinicians should be aware of this adverse reaction... - Thioguanine nucleotides and thiopurine methyltransferase in immunobullous diseases: optimal levels as adjunctive tools for azathioprine monitoringRokea A el-Azhary
Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Arch Dermatol 145:644-52. 2009..To prospectively determine optimal levels of 6-thioguanine nucleotide for disease remission in patients with immunobullous disease treated with azathioprine... - Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalizationRokea A el-Azhary
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Dermatol 44:25-8. 2005..A 63-year-old man with therapy-resistant Sézary syndrome was enrolled in a multicenter trial of oral bexarotene for advanced-stage cutaneous T-cell lymphoma (CTCL)... - Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patientsSaskia A Bouwhuis
Departments of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Am Acad Dermatol 52:991-6. 2005..It is possible that bexarotene contributed to this progression. Although bexarotene therapy may alleviate symptoms and signs of cutaneous T-cell lymphoma, careful surveillance of lymph nodes and solid organs during treatment is advised... - Patch test results may vary depending on where testing is performed: a comparison of patch test results from three geographically distinct sites in the USAMark D P Davis
Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA
Int J Dermatol 50:1353-61. 2011..Do patch test results vary from one part of the USA to another? Few reports directly compare the results of patch testing across centers within the USA... - Results of patch testing to personal care product allergens in a standard series and a supplemental cosmetic series: an analysis of 945 patients from the Mayo Clinic Contact Dermatitis Group, 2000-2007David A Wetter
Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA
J Am Acad Dermatol 63:789-98. 2010..Patch testing to a standard screening series of allergens in combination with supplemental cosmetic allergens is often used to diagnose allergic contact dermatitis due to personal care products... - Changing trends and allergens in the patch test standard series: a mayo clinic 5-year retrospective review, january 1, 2001, through december 31, 2005Mark D P Davis
Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Arch Dermatol 144:67-72. 2008..To present and interpret results of patch testing with the Mayo Clinic standard series over 5 years... - Treatment of late-stage Sézary syndrome with 2-ChlorodeoxyadenosineSaskia A Bouwhuis
Department of Dermatology and the Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Int J Dermatol 41:352-6. 2002..It can be used if no other suitable alternatives are available. Caution should be exercised in all these patients regarding skin care and avoidance of infections or sepsis... - Patch test results from the Mayo Clinic Contact Dermatitis Group, 1998-2000David A Wetter
Mayo Clinic Contact Dermatitis Group, Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Am Acad Dermatol 53:416-21. 2005..05) were observed for 12 of the 43 allergens common to both Mayo Clinic and the NACDG. CONCLUSION: With large standard patch test series, one can identify commonly encountered and potentially relevant contact allergens... - The contact allergen replacement database and treatment of allergic contact dermatitisJoseph M Kist
Department of Dermatology and the Section of Biostatistics, Mayo Clinic, Scottsdale, AZ 85259, USA
Arch Dermatol 140:1448-50. 2004..We anticipate an expanded clinical role for this database as an Internet-based resource... - Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndromeSaskia A Bouwhuis
Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Am Acad Dermatol 47:63-7. 2002..IDDM was documented in only 2 patients with a good response and in no patients with a partial response to ECP. CONCLUSION: Patients with Sézary syndrome and IDDM typically respond poorly to the standard ECP treatment regimen... - Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experienceDavid A Wetter
Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 80:41-7. 2005..Further studies are needed to verify the efficacy of IVIg for skin disease... - A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndromeWilliam G Morice
Division of Hematopathology, Mayo Clinic, Rochester, MN 55905, USA
Am J Clin Pathol 125:364-74. 2006.... - Relapsed hepatosplenic T-cell lymphoma heralded by a solitary skin noduleThomas L Hocker
Department of Dermatology, Mayo Clinic, Rochester, MN, USA
J Cutan Pathol 38:899-904. 2011..To our knowledge, this report provides the first detailed account of cutaneous involvement by HSTL. We show the novel utility of FISH to identify isochromosome 7q in the lesional skin of HSTL patients... - A 10-year retrospective study on palladium sensitivityOlayemi Durosaro
Department of Dermatology and Mayo Medical School, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Dermatitis 20:208-13. 2009..Palladium has become an important contact allergen because of increased use in industry, jewelry, and dentistry... - Fatal cytotoxic cutaneous lymphoma presenting as ulcerative psoriasisRoger H Weenig
Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA
Arch Dermatol 145:801-8. 2009..Psoriasis is a common, nonulcerative skin disorder... - Results of patch testing to a corticosteroid series: a retrospective review of 1188 patients during 6 years at Mayo ClinicMark D P Davis
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Am Acad Dermatol 56:921-7. 2007..Allergy to topical corticosteroids is more common than previously realized. To detect this allergy, a corticosteroid series is used for patch testing in addition to corticosteroid screens on a standard series... - Oral metal contact allergy: a pilot study on the cause of oral squamous cell carcinomaFiras G Hougeir
Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
Int J Dermatol 45:265-71. 2006..CONCLUSION: Contact allergy to metal dental restorations may be a risk factor for development of intraoral squamous cell carcinoma... - Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patientsAieska de Souza
Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA
J Am Acad Dermatol 61:993-1000. 2009..Lymphomatoid papulosis (LyP) is a cyclic papulonodular eruption that is clinically benign and histologically malignant. Association with hematologic neoplasias has been reported in 5% to 20% of all cases... - Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patientsTodd W Rozycki
Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA
J Am Acad Dermatol 46:27-34. 2002..Side effects were rare and minor. CONCLUSIONS: In this retrospective case series of 13 patients, topical tacrolimus was well tolerated and appeared to be an effective therapy to control symptoms and clear lesions of OLP... - Allergic contact dermatitis to epoxy resin in immersion oil for light microscopyRokea A el-Azhary
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Am Acad Dermatol 47:954-5. 2002..Positive patch test responses to epoxy resin, epoxy acrylate, and the immersion oil were noted. This case represents yet another contact allergic reaction, possibly airborne, to epoxy resin present in immersion oil used for microscopy... - Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritisDavid L Swanson
Department of Dermatology, Mayo Clinic, Scottsdale, Arizona 85259, USA
Int J Dermatol 46:157-9. 2007..Here, we aimed to investigate the effect of caffeine consumption on the methotrexate dosing requirements in patients with psoriasis and psoriatic arthritis... - Necrolytic migratory erythema: clinicopathologic study of 13 casesRamon M Pujol
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Dermatol 43:12-8. 2004..CONCLUSION: Increased awareness of the polymorphic mucocutaneous and nonspecific histopathologic features of glucagonoma syndrome is needed to avoid unnecessary delay in the diagnosis of this syndrome... - An atypical, painful foot ulcerJona K Gill
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Dermatol 41:692-3. 2002 - Does pancreas transplant in diabetic patients affect the evolution of necrobiosis lipoidica?Aieska D Souza
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Dermatol 48:964-70. 2009..To verify if reversal of the diabetic state is related to improvement of NL, we compared the evolution of NL lesions in patients who received a pancreas transplant with those who received a kidney... - Amyopathic dermatomyositis: retrospective review of 37 casesRokea A el-Azhary
Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Am Acad Dermatol 46:560-5. 2002..In most patients, amyopathic dermatomyositis does not progress to myopathy. Prognosis appears favorable, but malignancy may develop... - Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimensAlexander Meves
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Am Acad Dermatol 55:642-6. 2006..We conclude that early testing of skin biopsy specimens using fluorescent in situ hybridization in sex-mismatched patients with orthotopic liver transplantation can serve as an early diagnostic tool for graft-versus-host disease... - Pityriasis rubra pilaris in childrenDawn S Allison
Department of Dermatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
J Am Acad Dermatol 47:386-9. 2002..Retinoids should be considered as first-line treatment for PRP. Recurrence rate, previously thought to be rare, was about 17% in our population... - Do antihistone autoantibodies reflect disease activity in linear scleroderma?Rokea A el-Azhary
Arch Dermatol 140:759-60. 2004 - Rituximab: applications in dermatologyMitra M Fatourechi
University of Minnesota Medical School, Minneapolis, USA
Int J Dermatol 45:1143-55; quiz 1155. 2006..Clinical trials are lacking and would be an appropriate next step...